| Authors: |
Rutter MK; Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.; Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK., Mount J; Eli Lilly and Company, Basingstoke, UK., Gibson JM; Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.; NorthWest EHealth (NWEH) Ltd., Manchester, UK., Webb J; Eli Lilly and Company, Basingstoke, UK., Marler C; Eli Lilly and Company, Indianapolis, Indiana, USA., Reed C; Eli Lilly and Company, Basingstoke, UK., Gore M; Eli Lilly and Company, Indianapolis, Indiana, USA., Ye W; Eli Lilly and Company, Indianapolis, Indiana, USA., Gomez Valderas E; Eli Lilly and Company, Indianapolis, Indiana, USA., Wilding J; Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK., Sattar N; School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK., Davies MJ; Diabetes Research Centre, University of Leicester, Leicester, UK.; NIHR Leicester Biomedical Research Centre, Leicester, UK., Khunti K; Diabetes Research Centre, University of Leicester, Leicester, UK., Haynes R; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Batterham RL; Eli Lilly and Company, Basingstoke, UK. |
